【hammer not urethane】As Biotech Thrives On Vaccine Hopes, Traders Look Into The Sector's Diversity
If there is hammer not urethaneone prevailing trend that Wall Street is counting on during this period of great economic and social uncertainty, it’s the promise of biotech and pharmaceutical companies to seemingly save the world.
At the very least, they’re relying on the sector to save the market. Throughout 2020, returns from healthcare indexes such as the Russell 1000 Healthcare Index and the MSCI World Health Care Index have routinely outperformed broad market indexes like the S&P 500 and MSCI Europe and Asia Indexes. What’s more, the latest earnings results from the sector have shown
nearly 90% of companies exceeding analyst expectations
.
2020 Index Performances By Total Returns
pph_marketperf_2020.11.png
Source: Factset; Data as of November 16, 2020
Because of the growth outlook for the sector and the massive amount of interest surrounding it, trading research platform
VantagePoint
plans to focus on biotech and other exciting market sectors in an
upcoming free demonstration
of the predictive software’s A.I.-enhanced features.
In anticipation of the live demonstration, let’s take a look at some of the biggest movers in the biotech sector currently as well as some of the factors influencing their price moves.
The Pandemic Seizes The Market
Of course, Many of the major constituents driving growth in the biotech and pharmaceutical sector are tied in with the research and development of various vaccines, treatments and testing apparatuses aimed at combating the ongoing COVID-19 pandemic. And with news and trial results emerging and evolving on a near daily basis, traders are discovering new avenues by which to profit from the sector.
Don’t get caught off-guard again, learn how Predictive A.I. can improve your trades
While positive late-stage vaccine trial results from the likes of
BioNTech SE
(NASDAQ:
BNTX
) and
Novavax
(NASDAQ:
NVAX
), alongside or in partnership with pharmaceutical giants like
Pfizer Inc
. (NYSE:
PFE
) and
Moderna, Inc
. (NASDAQ:
MRNA
), have obviously boosted the valuation of these companies. Each of these stocks are sitting at or near 52-week highs heading into December.
However, in addition to following the breaking news on these stocks, traders have also gravitated toward other companies involved in developing alternative vaccines or treatment in the wake of the advance guard.
Growth Throughout The Industry
Because while the leading COVID-19 vaccine candidates have garnered a high price tag, there are an array of follow-up companies that aim to deliver vaccines and treatments with different mechanisms of action from those currently dominating the headlines.
Story continues
This includes firms like
Inovio Pharmaceuticals, Inc.
(NASDAQ:
INO
) and
AstraZeneca PLC
(NASDAQ:
AZN
), which stocks have both wavered as they have trailed Moderna and Pfizer in producing successful trial results in their respective vaccine formulations.
However, as vaccine approval and distribution ramps up and supply chain and efficacy issues begin to influence the market, additional news from Inovio and AstraZeneca may prove critical as the world attempts to find the quickest and safest path away from the pandemic.
Discover how VantagePoint’s predictive analysis could help you avoid potential losses
Another stock with potential surprise in store is
Merck & Co, Inc
. (NYSE:
MRK
). Although relatively quiet through the race for a vaccine, the company
has invested heavily in M&A
in an attempt to round out their vaccine research. Add to that the firm’s strong Q3 earnings report that well surpassed analyst expectations and even showed modest year-over-year growth and Merck stands as something of a dark horse in the biotech sector.
Anticipate The Unexpected
Ultimately, there is still a good deal of uncertainty still at play in the market thanks to the persistence of the global pandemic.
While biotech may be a prime driver of equity as the market’s hopes for a quick recovery outweigh its fear of the virus, traders should nonetheless leverage the best in institutional-level technology and analysis to anticipate market trends up to three days in advance.
To find out more,
click here to sign up
for an upcoming demonstration of VantagePoint’s cutting-edge research and analysis software.
See more from Benzinga
Click here for options trades from Benzinga
FlowerHire X Leverages Tech To Set A New Precedent In Fostering Talent In The Cannabis Industry
Are Gambling Stocks A Strong Bet In An Uncertain Market?
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
-
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue EstimatesUffizi Gallery Asks Germany to Return Dutch Masterpiece Nazis Stole in World War IIWhat Kind Of Shareholder Owns Most Century Legend (Holdings) Limited (HKG:79) Stock?Apple Is a Mega-Cap Stock That You Should Consider NowPeak Announces Initiation of Research Coverage by eResearchWorld stocks edge down ahead of US jobs reportDoes Cosmo Pharmaceuticals N.V.’s (VTX:COPN) CEO Salary Compare Well With Others?BRIEF-Rizhao Port's Controlling Shareholder's Unit Wins Project For 243.5 Million YuanRohingya must have choice on going to Bangladesh island - UN refugee agencyNatural Gas Price Fundamental Daily Forecast – Bouncing Back After Hitting More Than 3-Month Low
- ·BRIEF-Wangfujing Group, BTG Hotels' Chairman Passed Away Due To Illness
- ·‘The Bear’ Fans Notice a Potential Continuity Error During Tina’s Backstory Episode in Season 3
- ·Boasting A 22% Return On Equity, Is Triveni Turbine Limited (NSE:TRITURBINE) A Top Quality Stock?
- ·Judge Considers Gag Order in Warning to Roger Stone
- ·Facebook warned it may lose a key seal of approval for ad measurement - WSJ
- ·Could The Finning International Inc. (TSE:FTT) Ownership Structure Tell Us Something Useful?
- ·The top iPhone and iPad apps on App Store
- ·Middleby Buys EVO America, Expands Ventless Cooking Business
- ·Were Hedge Funds Right About Automatic Data Processing (ADP)?
- ·Trade deficit shrank more than expected
- ·AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
- ·Brazil's new far-right government issues decrees across sectors
- ·A Magnificent Ascent For The Newest Cloud ETF
- ·‘Bitcoin is a Garbage Network’: Fortune 500 Software Developer
- ·What Kind Of Investor Owns Most Of Krakatoa Resources Limited (ASX:KTA)?
- ·BRIEF-Kasen International Holdings Says Expected To Record Consol Net Profit Attributable For Year
- ·Insider Buying: The Mitchell Services Limited (ASX:MSV) Executive Chairman Just Bought AU$53k Worth Of Shares
- ·Top 5 Things to Know in the Market on Friday
- ·Cathay Pacific mistakenly sells $16,000 flight for $675
- ·BRIEF-Zhi Cheng Holdings Enters MOC With Beijing Feiyang Shidai Cultural Industry
- ·Merck (MRK) Stock Moves -0.81%: What You Should Know
- ·Does China e-Wallet Payment Group Limited (HKG:802) Have A Particularly Volatile Share Price?
- ·Alleged Saudi ballistic missile base signals greater divergence from Washington, experts say
- ·Zacks Rank #5 Additions for Monday
- ·Paycom Software, Inc. to Host Earnings Call
- ·The Super Bowl is worth billions each year — Here's who makes what
- ·What Is Parker-Hannifin's (NYSE:PH) P/E Ratio After Its Share Price Tanked?
- ·Facebook removes hundreds of pages and groups in Indonesia
- ·Could The Finning International Inc. (TSE:FTT) Ownership Structure Tell Us Something Useful?
- ·How Karoon Energy Ltd (ASX:KAR) Can Impact Your Portfolio Volatility
- ·XFC to Live Stream Inaugural Try-Outs in Michigan on Sept 12 Live on Location at Team SFS-Scorpion Fighting System
- ·U.S. Dollar Mixed As Weak Asian Data Offset Signs of Trade Progress
- ·Overseas unit of China's cigarette monopoly files for Hong Kong IPO
- ·Does Mediacontech S.p.A. (BIT:MCH) Have A Particularly Volatile Share Price?
- ·Top Analyst Reports for Apple, Verizon & PayPal
- ·Jason Bateman says he nearly 'ran over' Michael Jackson with his bicycle as a kid